Novel ligands for P2 receptor subtypes in innervated tissues.
Prog Brain Res
; 120: 107-17, 1999.
Article
in En
| MEDLINE
| ID: mdl-10550991
ABSTRACT
Among suramin analogues, the properties of P2 receptor subtype blockade and ecto-nucleotidase inhibition appear to be controlled by different structural parameters (Fig. 1 and 2, Table 1; Van Rhee et al., 1994; Beukers et al., 1995; Bültmann et al., 1996; Damer et al., 1998a, 1998b; and this study) the molecular size of the compounds, the position of the sulfonic acid residues in the naphthalene rings, the substitution pattern of the benzoyl moieties and the 3'- or 4'-aminobenzoyl-linkages of the phenyl rings "1" and "2". As a result, compounds with different receptor selectivity profiles were obtained. A maximum in potency at and selectivity for P2X1 receptors is reached in NF279, which is a specific P2 receptor antagonist and the compound with the highest P2X1 vs. P2Y receptor and ecto-nucleotidase selectivity presently available.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Suramin
/
Adenosine Triphosphate
/
Receptors, Purinergic P2
Limits:
Animals
Language:
En
Journal:
Prog Brain Res
Year:
1999
Document type:
Article